Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03536143 · ClinicalTrials.gov registry record · Phase 1
A Phase I/II Study of KB103, a Topical HSV1-COL7, on DEB Patients
A Phase 1 study of Dystrophic Epidermolysis Bullosa, sponsored by Krystal Biotech.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT03536143 is a Phase 1 study of Dystrophic Epidermolysis Bullosa that has completed, run by Krystal Biotech. The registered enrollment target is 12 participants, below the 19-participant average among 7 other Dystrophic Epidermolysis Bullosa trials with a reported enrollment target (37% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03536143, a Phase 1 study of Dystrophic Epidermolysis Bullosa, has completed, sponsored by Krystal Biotech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This study was conducted to assess the safety and efficacy of topical Beremagene Geperpavec (KB103, HSV1-COL7) on DEB patients.
Conditions Studied
Interventions
- BIOLOGICAL Topical beremagene geperpavec
- BIOLOGICAL Placebo gel
Study Locations (1)
California
- Stanford University - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2018-05-06 |
| Est. Completion | 2019-11-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03536143
The ClinicalTrials.gov registry entry for NCT03536143 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 19-participant average among 7 other Dystrophic Epidermolysis Bullosa trials with a reported enrollment target (37% lower). The listed sponsor is Krystal Biotech, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dystrophic Epidermolysis Bullosa appearing as the primary indexed condition, and to 2 interventions - of which Topical beremagene geperpavec is the first listed.
NCT03536143 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03536143 about?
NCT03536143 is a clinical study titled "A Phase I/II Study of KB103, a Topical HSV1-COL7, on DEB Patients". This study was conducted to assess the safety and efficacy of topical Beremagene Geperpavec (KB103, HSV1-COL7) on DEB patients.
What is the current status of trial NCT03536143?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2018-05-06. Estimated completion is 2019-11-01.
What conditions does trial NCT03536143 study?
This clinical trial studies the following conditions: Dystrophic Epidermolysis Bullosa.
What interventions are being tested in trial NCT03536143?
The interventions under investigation include: Topical beremagene geperpavec (BIOLOGICAL), Placebo gel (BIOLOGICAL).
Who is sponsoring clinical trial NCT03536143?
This trial is sponsored by Krystal Biotech, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03536143 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dystrophic Epidermolysis Bullosa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa
RECRUITING · Phase 1
-
MSC EVs in Dystrophic Epidermolysis Bullosa
RECRUITING · Phase 1
-
To Evaluate the Pharmacokinetic of Diacerein and Rhein After Maximum Use in Patients With Epidermolysis Bullosa (EB)
COMPLETED · Phase 1
-
A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa
RECRUITING · Phase 3
-
Long-Term Follow-up Protocol
RECRUITING
-
Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET in Subjects With Dystrophic Epidermolysis Bullosa
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.